Alnylam posts Q4 net product rev $995M (+121%); achieves full-year GAAP profitability

ALNYLAM PHARMACEUTICALS, INC.

2025-FY EPS reported $2.33 revenue$3,713,937,000

Q4 2025 net product revenue $995M (+121% YoY); full-year $2,987M (+81%); total revenue Q4 $1.1B.
GAAP net income $111.5M ($0.82 diluted EPS) vs. loss a year ago; full-year GAAP net income $313.7M.
Non-GAAP operating income $849.8M for FY2025; company expects sustainable operating income growth.
AMVUTTRA (ATTR-CM) drove TTR franchise: Q4 $827M, full year $2,314M (+103% YoY).
Launches 'Alnylam 2030' strategy; plans $250M manufacturing expansion; board appoints Stuart Arbuckle.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.